Indivior Pharmaceuticals, Inc. clinical trials

The registry lists 54 studies whose lead sponsor is Indivior Pharmaceuticals, Inc. or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 54. Browse all 54 →

• INDV-6001 Multiple-Dose Pharmacokinetic StudyCompletedNCT06576843Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk UsersCompletedNCT04995029Phase 4

  Sponsor listed in the registry: Indivior Inc.

• Evaluating the SUBLOCADE Treatment Exit StrategyCompletedNCT05878210

  Sponsor listed in the registry: Indivior Inc.

• Proof of Concept and Dose-ranging Study of INDV-2000 in Individuals With Moderate to Severe Opioid Use DisorderCompletedNCT06384157Phase 2

  Sponsor listed in the registry: Indivior Inc.

• SUBLOCADE Long-term OutcomesCompletedNCT05860959

  Sponsor listed in the registry: Indivior Inc.

• Pharmacodynamic Evaluation of Intranasal NalmefeneCompletedNCT04828005Phase 1

  Sponsor listed in the registry: Opiant Pharmaceuticals Inc · First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc.

• SUBLOCADE Rapid Initiation StudyCompletedNCT03993392Phase 4

  Sponsor listed in the registry: Indivior Inc.

• SUBLOCADE Rapid Initiation Extension StudyCompletedNCT04060654Phase 4

  Sponsor listed in the registry: Indivior Inc.

• Buprenorphine-Fentanyl Interaction StudyCompletedNCT03747341Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Single Dose Study of [14C]-IDV184001AN ([14C]-IDV184001) in Healthy Adult Male ParticipantsCompletedNCT05974046Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Evaluation of Buprenorphine Extended-Release Subcutaneous Injection at Alternative Injection LocationsCompletedNCT05704543Phase 4

  Sponsor listed in the registry: Indivior Inc.

• Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use DisorderCompletedNCT04976855Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Pharmacokinetic Evaluation of Intranasal NalmefeneCompletedNCT04759768Phase 1

  Sponsor listed in the registry: Opiant Pharmaceuticals Inc · First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc.

• Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing RegimensCompletedNCT05219669Phase 1

  Sponsor listed in the registry: Opiant Pharmaceuticals Inc · First submitted before Opiant Pharmaceuticals Inc became part of Indivior Pharmaceuticals, Inc.

• Study of Potential CYP3A4 Induction by INDV-2000 in Healthy AdultsCompletedNCT05694533Phase 1

  Sponsor listed in the registry: Indivior Inc.

• INDV-2000 First in HumanCompletedNCT04413552Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)CompletedNCT01075971Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Preference for Subutex® (Buprenorphine) Versus Suboxone® (Buprenorphine/Naloxone) in Opioid Dependent Patients on Subutex® (Study P05094)(COMPLETED)CompletedNCT00684073Phase 4

  Sponsor listed in the registry: Indivior Inc.

• Observational Study of Misuse of High Dose Buprenorphine (Subutex® or Generic) in Opiate-Addicted Patients in France (Study P05186AM1)(COMPLETED)CompletedNCT00723697

  Sponsor listed in the registry: Indivior Inc.

• Survey of Buprenorphine Use Among "Out of Care" Population in France (P04933)(COMPLETED)CompletedNCT00756353

  Sponsor listed in the registry: Indivior Inc.

• An Observational Study of Environmental and Socioeconomic Factors in Opioid Recovery - Long TermTerminatedNCT04577144

  Sponsor listed in the registry: Indivior Inc.

• Safety, Tolerability, Pharmacokinetics and Efficacy of 180 mg Subcutaneous Risperidone From 6 mg Oral RisperidoneCompletedNCT03978832Phase 4

  Sponsor listed in the registry: Indivior Inc.

• Evaluation of Long-term Buprenorphine Plasma ExposureCompletedNCT03752528

  Sponsor listed in the registry: Indivior Inc.

• An Observational Study of Environmental and SocioEconomic Factors in Opioid RecoveryCompletedNCT03604861

  Sponsor listed in the registry: Indivior Inc.

• Study of a Novel Subcutaneous Depot Formulation of BuprenorphineCompletedNCT03715634Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Open-Label Treatment Extension StudyCompletedNCT02896296Phase 3

  Sponsor listed in the registry: Indivior Inc.

• Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia PatientsCompletedNCT02109562Phase 3

  Sponsor listed in the registry: Indivior Inc.

• Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/EfficacyCompletedNCT01677377Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Long Term Study of RBP 7000 in the Treatment of Subjects With SchizophreniaCompletedNCT02203838Phase 3

  Sponsor listed in the registry: Indivior Inc.

• Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid DisorderCompletedNCT02044094Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use DisorderCompletedNCT02510014Phase 3

  Sponsor listed in the registry: Indivior Inc.

• Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent SubjectsCompletedNCT01738503Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of BuprenorphineCompletedNCT02357901Phase 3

  Sponsor listed in the registry: Indivior Inc.

• A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy VolunteersCompletedNCT03058237Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/NaloxoneCompletedNCT00637000Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent PopulationCompletedNCT02038790Phase 4

  Sponsor listed in the registry: Indivior Inc.

• Acceptability and Safety of Switching From Subutex or Other Opioid Drug Dependence Therapy to Suboxone (NIS P05444)CompletedNCT00725608

  Sponsor listed in the registry: Indivior Inc.

• Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use DisorderCompletedNCT02559973Phase 1

  Sponsor listed in the registry: Indivior Inc.

• PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With SchizophreniaCompletedNCT02687984Phase 1

  Sponsor listed in the registry: Indivior Inc.

• A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use DisorderCompletedNCT02511886Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Transfer of Subjects From Subutex/Suboxone to RBP-6300CompletedNCT01582347Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Single Ascending Dose Study of RBP-6000CompletedNCT03002961Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired SubjectsCompletedNCT01846455Phase 4

  Sponsor listed in the registry: Indivior Inc.

• A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)CompletedNCT00605033Phase 4

  Sponsor listed in the registry: Indivior Inc.

• A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine AbuseCompletedNCT01846481Phase 2

  Sponsor listed in the registry: Indivior Inc.

• A Study to Evaluate the Efficacy and Safety of Controlled Release Arbaclofen Placarbil (XP19986) in Patients With Gastroesophageal Reflux DiseaseCompletedNCT00838396Phase 2

  Sponsor listed in the registry: Indivior Inc.

• Single Ascending Dose Study of RBP-7000CompletedNCT02768649Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Single-dose, Study of RBP-6000 in Opioid Dependent IndividualsCompletedNCT02765867Phase 1

  Sponsor listed in the registry: Indivior Inc.

• First in Man Study of Safety, Tolerability and PK Profile of RBP-7000CompletedNCT02765555Phase 1

  Sponsor listed in the registry: Indivior Inc.

• Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME")CompletedNCT00955162Phase 4

  Sponsor listed in the registry: Indivior Inc.